Market Research Logo

Biobanking: Technologies and Global Markets

Biobanking: Technologies and Global Markets

The global market for biobanking technologies was valued at $186.3 billion in 2015. This market is expected to increase from $198.2 billion in 2016 to $240.2 billion in 2021 at a compound annual growth rate (CAGR) of 3.9% for 2016-2021.

This report provides:
An overview of the global markets for biobanking, the storage of biological samples for the future.
Analyses of global market trends, with data from 2015, estimates for 2016 and projections of compound annual growth rates (CAGRs) through 2021.
Detailed analyses of how biobanks can lead to new products for specific diseases to overall industry trends.
Breakdowns of the biobanking market by product, disease category, and geographic region or country.
New products approved by the FDA, and those products expected to be approved within the forecast period.
Analysis of the leading competitors, as well as emerging companies in the current worldwide biobanking market.
Profiles of the manufacturers of leading products, and their specific product strategies are outlined.


SCOPE OF REPORT

This report entails forecasted and prevailing biobank products within the 2016 to 2021 period. Biobanks play a critical role in the development of new drugs. The document also features new FDA-approved products in 2015 and 2016, as well as those awaiting approval within the forecast period. The 2016 figures in this report are approximated except in cases where reports of exact results have been released; this is attributed to the timing of this report’s release.

Emerging companies and the leading competitors in the prevailing global Biobanks industry are analyzed extensively in this report. The specific product strategies and products of leading drug manufacturers in the market are analyzed and profiled in the report. Biotechnology companies that utilize biobanks to develop new, novel products are also included in the analysis. New products expected to be introduced in the market within the forecast period and their manufacturers, in addition to their impact on the competitive biobank market are discussed in this report. The competitive market environment is evaluated with a unique emphasis on the effect of the new technologies and products on the prevailing patient care standard. Emerging companies and current leaders in the market are profiled and discussed in detail.

Market figures are founded on the revenue level of the manufacturers and forecast done in the 2016-dollar value. Forecast figures exclude inflation. Parameters like the introduction of new products, forecast sales for prevailing products, expanded indications for prevailing products and forecasted changes in the rates of diagnosis, prevalence and scripting for specific diseases are considered when assessing trends.

Forecasts featured in this report for the period between 2016 and 2021 are based on disease category, product and company. The study is organized for an overview of the biobanks market by geography, company and product. The projections are based on country or geographic region. For every disease sub-segment, the global market is evaluated and data provided.

Consumables that do not require prescription from a physician like over-the-counter (OTC) drugs are not covered in this report.

Sales figures are in U.S. dollars, with each reflecting change in revenue performance due to currency fluctuations. Variations in local currencies, however, are not accounted for by the revenue figures.

Unless pointed out, all data on market share in the report are on a global basis.

CHAPTER 1 INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE OF REPORT
INTENDED AUDIENCE
ANALYST'S CREDENTIALS
METHODOLOGY AND INFORMATION SOURCES
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 SUMMARY
SUMMARY TABLE GLOBAL MARKET FOR BIOBANKS BY SEGMENT, THROUGH 2021 ($ BILLIONS)
SUMMARY FIGURE GLOBAL MARKET FOR BIOBANKS BY SEGMENT, 2015-2021 ($ BILLIONS)
CHAPTER 3 OVERVIEW
CURRENT STATE OF THE INDUSTRY
THE PROCESS OF BIOBANKING
HISTORICAL CONTEXT
SCIENTIFIC AND COMMERCIAL RELEVANCE OF BIOBANKS
TABLE 1 CUMULATIVE NUMBER OF DNA SAMPLES BANKED IN POPULATION-BASED STUDIES*, 1970-2015
TABLE 2 VALUE OF DNA SAMPLES STORED, THROUGH 2021
TABLE 3 NIH SPONSORED CLINICAL TRIALS CONDUCTING GENE EXPRESSION PROFILING, 2000-2014* (CUMULATIVE NUMBER OF NIH -SPONSORED CLINICAL TRIALS)
Modern Biobanks
BIOBANKING COSTS
DRIVERS OF BIOBANKS GROWTH
RESISTORS OF BIOBANKS GROWTH
BIOBANKING TRENDS AND FORECAST
THE ROLE OF BIOBANKS IN FUTURE BIOMEDICAL DISCOVERIES
CHAPTER 4 OVERVIEW OF BIOBANK APPLICATIONS
TABLE 4 GLOBAL MARKET FOR BIOBANKING BY APPLICATION, THROUGH 2021 ($ MILLIONS)
BIOMARKERS
TABLE 5 SELECTED CANCER BIOBANKS IN THE U.S.
TABLE 6 GLOBAL MARKET FOR BIOMARKERS IN LATE STAGE CLINICAL USE BY THERAPEUTIC AREA, THROUGH 2021 ($ MILLIONS/%)
OPPORTUNITIES IN CANCER
TABLE 7 APPLICATION OF BIOBANKS IN CANCER TREATMENT
TABLE 8 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: ONCOLOGY
OPPORTUNITIES IN CARDIOVASCULAR DISEASE
TABLE 9 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:
CARDIOVASCULAR
OPPORTUNITIES IN NEUROLOGICAL DISEASES
THE BRAIN AND THE CENTRAL NERVOUS SYSTEM
TABLE 10 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE
OPPORTUNITIES IN IMMUNOLOGY
AUTOIMMUNE DISEASES
TABLE 11 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:
IMMUNOLOGY
SYSTEMIC LUPUS ERYTHEMATOSUS
ALZHEIMER'S DISEASE
OTHER OPPORTUNITIES RESULTING FROM BIOBANKS
TARGETED THERAPEUTICS
DIAGNOSTIC AND PROGNOSTIC TESTS
Diagnostic Tests
Prognostic Tests
DRUG DEVELOPMENT
DISEASE ETIOLOGY
CHAPTER 5 CURRENT BIOBANKS WORLDWIDE
OVERVIEW
TABLE 12 GLOBAL MAJOR BIOBANKS LOCATIONS, BY COUNTRY, 1998-2009
TABLE 13 TYPES OF BIOBANKS
U.S. BIOBANKS
TABLE 14 MAJOR NHLBI COHORT STUDIES
TABLE 15 EXAMPLES OF MAJOR DISEASE-BASED BIOBANKS
EUROPEAN BIOBANKS
THE UNITED KINGDOM
UK Biobank
Licensed Biobanks in The U.K.
TABLE 16 ESTABLISHMENTS LICENSED TO OPERATE BIOBANKS IN THE U.K., 2016
TABLE 17 FUNDING SOURCES FOR BIOBANKS LICENSED IN THE U.K. (%)
Biobank and Biomolecular Resource Research Infrastructure
TABLE 18 COMPOSITE FUNDING METHODS FOR BIOBANKS IN BBMRI COUNTRIES (%)
TABLE 19 DISTRIBUTION OF BIOBANKS IN EU COUNTRIES
TABLE 20 OWNERSHIP OF EUROPEAN BIOBANKS (%)
TABLE 21 ACCESS TO THE EUROPEAN BIOBANK (%)
BIOBANKS IN NORTHERN EUROPE
Biobanks in Denmark
Biobanks in the Baltic Countries
INTERNATIONAL BIOBANKS IN OTHER PARTS OF THE WORLD
Canadian Partnership for Tomorrow Project
Far East Biobanks
China Biobank
The Qatar Biobank
Middle East Biobanks
CHAPTER 6 DISEASE-BASED BIOBANKS
GROWTH IN DISEASE-BASED BIOBANKS
TABLE 22 GROWTH IN DISEASE-BASED BIOBANKS BY THERAPY IN THE U.S., 2007-2014
CANCER BIOBANKS
BIOBANKS FOR OTHER DISEASES
HEALTHY SAMPLE BIOBANKS
COLLABORATIVE NETWORKS
CORE UK
INTERNATIONAL GENOMICS CONSORTIUM
CANCER GENOME ATLAS
SEGMENT FORECAST
CHAPTER 7 POPULATION BASED BIOBANKS
INTRODUCTION
TYPES OF POPULATION BIOBANKS
COHORT STUDIES
TABLE 23 SELECTED POPULATION-BASED COHORT BIOBANKS, 1976-2009
FOUNDER POPULATION BIOBANKS
TABLE 24 FOUNDER POPULATION-BASED BIOBANKS
DECODE GENETICS
CARTAGENE
GENIZON BIOSCIENCES
JURILAB
NATIONAL POPULATION BIOBANKS
UK BIOBANK
LIFEGENE
ESTONIAN BIOBANK
LATVIAN BIOBANK
CANADIAN PARTNERSHIP FOR TOMORROW PROJECT
OTHER NATIONAL BIOBANKS
CHAPTER 8 FOR-PROFIT BIOBANK COMPANIES
CONTRACT BIOBANK AND SERVICE PROVIDERS
BIOMARKER DISCOVERY COMPANIES
PHARMACEUTICAL COLLECTIONS
RESEARCH COLLABORATIONS
CLINICAL TRIALS
CHAPTER 9 THE LIMITATIONS OF BIOBANKS
SAMPLE VARIABILITY
SAMPLE QUALITY
EFFORTS TO INCREASE HARMONIZATION
INITIATIVES TO IMPROVE BIOBANKS
CHAPTER 10 REGULATORY DYNAMICS, INTELLECTUAL PROPERTY, ETHICAL CONSIDERATIONS
INTRODUCTION
ROLE OF THE FOOD & DRUG ADMINISTRATION
CURRENT REGULATORY FRAMEWORK
INFORMED CONSENT
WITHDRAWAL AND OWNERSHIP
CONFIDENTIALITY
COMMERCIALIZATION
FDA GUIDELINES FOR BIOMARKER APPLICATIONS
TABLE 25 FDA GUIDELINES FOR BIOMARKER APPLICATIONS
EUROPEAN MEDICINES AGENCY
REGULATORY IMPACT ON DRUG SAFETY
INTELLECTUAL PROPERTY AND COMPETITIVE POSITIONING
APPROVED PATENT ANALYSIS
TABLE 26 GLOBAL ANNUAL PATENTS FILED AND APPROVED WITH BIOMARKER CLAIMS BY REGION, THROUGH 2016
COMPETITIVE LANDSCAPE
LATE STAGE CLINICAL TRIALS: COMPETITIVE POSITIONING
TABLE 27 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS BY SERVICES AND PRODUCTS, THROUGH 2021 ($ MILLIONS)
TABLE 28 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER DELIVERY
TABLE 29 REPRESENTATIVE LIST OF APPROVED BIOMARKER PATENTS
IN THE U.S., EUROPE AND JAPAN
ETHICAL CONSIDERATIONS
SUMMARY
REGULATORY IMPLICATIONS
CHAPTER 11 BIOBANK MARKETS FORECAST BY SEGMENT AND REGION
SUMMARY
TABLE 30 GLOBAL MARKET FOR BIOBANKS BY SEGMENT, THROUGH 2021 ($ BILLIONS)
GEOGRAPHIC MIX
TABLE 31 GLOBAL MARKET SHARE OF BIOBANKS BY REGION, 2015-2021 (%)
CHAPTER 12 DETAILED DESCRIPTION OF THE USE OF BIOMARKERS
COLORECTAL CANCER
CETUXIMAB
PANITUMUMAB
ELESCLOMOL
HERCEPTIN
OTHER PREDICTIVE TESTS
TABLE 32 CURRENT ACTIVE BIOMARKER TRIALS ONGOING: ONCOLOGY
BREAST CANCER
MAMMAPRINT
TABLE 33 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: BREAST CANCER, 2007-2009
ONCOTYPE DX
TEST ADOPTION
OTHER PROGNOSTIC TESTS
HORMONAL THERAPIES
TAXANES/ANTHRACYCLINES
TRIPLE NEGATIVE BREAST CANCER
OTHER NOVEL BIOMARKERS
LUNG CANCER
INTRODUCTION
PREDICTIVE TESTS
TABLE 34 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: LUNG CANCER, 2006-2014
GEFITINIB
ERLOTINIB
OTHER PREDICTIVE TESTS
NOVEL THERAPIES
PROSTATE CANCER
OVARIAN CANCER
MALIGNANT MELANOMA
TABLE 35 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: MALIGNANT MELANOMA, 2006-2016
CARDIOVASCULAR
TABLE 36 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CARDIOVASCULAR, 2010-2014
CENTRAL NERVOUS SYSTEM
TABLE 37 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE, 2010-2013
TABLE 38 BIOMARKERS/TEST FOR OTHER NEUROLOGICAL DISEASES, 2008-2009
IMMUNOLOGY- AUTOIMMUNE DISEASES
TABLE 39 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: IMMUNOLOGY, 2009-2014
IMMUNOLOGY
BENLYSTA: HUMAN GENOME SCIENCES
EXPEDITION AND IDENTITY ALZHEIMER’S TRIAL: ELI LILLY
CHAPTER 13 COMPANY ANALYSIS
ABBOTT LABORATORIES INC.
COMPANY OVERVIEW
PRODUCTS AND SERVICES
TABLE 40 ABBOTT REPRESENTATIVE CLINICAL TRIALS INVOLVING
BIOMARKERS
COMPANY STRATEGY
AFFYMETRIX, INC.
COMPANY OVERVIEW
PRODUCTS AND SERVICES
COMPANY STRATEGY
ASTERAND PLC
COMPANY OVERVIEW
PRODUCTS AND SERVICES
TABLE 41 ASTERAND PRODUCTS OVERVIEW BY TYPE OF BIOBANK
COMPANY STRATEGY
ASTRAZENECA LTD
COMPANY OVERVIEW
PRODUCTS AND SERVICES
TABLE 42 ASTRAZENECA REPRESENTATIVE CLINICAL TRIALS
INVOLVING BIOMARKERS
COMPANY STRATEGY
BAYER SCHERING PHARMA AG
COMPANY OVERVIEW
PRODUCTS AND SERVICES
COMPANY STRATEGY
BIOCHAIN-GENOMICS
COMPANY OVERVIEW
PRODUCTS AND SERVICES
TABLE 43 BIOCHAIN-GENOMICS' PRODUCTS OVERVIEW BY TYPE OF BIOBANK
COMPANY STRATEGY
BIOSTORAGE TECHNOLOGIES, INC.
COMPANY OVERVIEW
PRODUCTS AND SERVICES
TABLE 44 BIOSTORAGE TECHNOLOGIES' PRODUCTS OVERVIEW BY TYPE OF BIOBANK
COMPANY STRATEGY
BOEHRINGER INGELHEIM GMBH
COMPANY OVERVIEW
PRODUCTS AND SERVICES
COMPANY STRATEGY
BRISTOL-MYERS SQUIBB CO
COMPANY OVERVIEW
PRODUCTS AND SERVICES
TABLE 45 BMS REPRESENTATIVE CLINICAL TRIALS INVOLVING
BIOMARKERS
COMPANY STRATEGY
DAIICHI SANKYO COMPANY, LTD
COMPANY OVERVIEW
PRODUCTS AND SERVICES
COMPANY STRATEGY
ELI LILLY AND COMPANY
COMPANY OVERVIEW
PRODUCTS AND SERVICES
TABLE 46 ELI LILLY REPRESENTATIVE CLINICAL TRIALS INVOLVING
BIOMARKERS
COMPANY STRATEGY
EXIQON LIFE SCIENCES
COMPANY OVERVIEW
PRODUCTS AND SERVICES
TABLE 47 EXIQON PRODUCTS OVERVIEW BY TYPE OF BIOBANK
COMPANY STRATEGY
GLAXOSMITHKLINE
COMPANY OVERVIEW
PRODUCTS AND SERVICES
TABLE 48 GSK REPRESENTATIVE CLINICAL TRIALS INVOLVING
BIOMARKERS
COMPANY STRATEGY
JOHNSON & JOHNSON LTD
COMPANY OVERVIEW
PRODUCTS AND SERVICES
COMPANY STRATEGY
MILLENNIUM PHARMACEUTICALS
COMPANY OVERVIEW
PRODUCTS AND SERVICES
TABLE 49 MILLENNIUM PRODUCTS OVERVIEW BY TYPE OF BIOBANK
COMPANY STRATEGY
MERCK & CO.
COMPANY OVERVIEW
PRODUCTS AND SERVICES
TABLE 50 MERCK REPRESENTATIVE CLINICAL TRIALS INVOLVING
BIOMARKERS
COMPANY STRATEGY
NOVARTIS AG
COMPANY OVERVIEW
PRODUCTS AND SERVICES
TABLE 51 NOVARTIS REPRESENTATIVE CLINICAL TRIALS INVOLVING
BIOMARKERS
COMPANY STRATEGY
PFIZER INC
COMPANY OVERVIEW
PRODUCTS AND SERVICES
TABLE 52 PFIZER REPRESENTATIVE CLINICAL TRIALS INVOLVING
BIOMARKERS
COMPANY STRATEGY
F. HOFFMAN-LA ROCHE AG
COMPANY OVERVIEW
PRODUCTS AND SERVICES
TABLE 53 ROCHE REPRESENTATIVE CLINICAL TRIALS INVOLVING
BIOMARKERS
COMPANY STRATEGY
SANOFI-AVENTIS
COMPANY OVERVIEW
PRODUCTS AND SERVICES
TABLE 54 SANOFI-AVENTIS REPRESENTATIVE CLINICAL TRIALS
INVOLVING BIOMARKERS
COMPANY STRATEGY
SCIPAC
COMPANY OVERVIEW
PRODUCTS AND SERVICES
TABLE 55 SCIPAC PRODUCTS OVERVIEW BY TYPE OF BIOBANK
COMPANY STRATEGY
TAKEDA PHARMACEUTICALS LTD
COMPANY OVERVIEW
PRODUCTS AND SERVICES
COMPANY STRATEGY
TEVA PHARMACEUTICAL INDUSTRIES LTD.
COMPANY OVERVIEW
PRODUCTS AND SERVICES
COMPANY STRATEGY

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report